US FDA to provide greater flexibility for new animal drug applications
This article was originally published in SRA
The US Food and Drug Administration has issued a direct final rule that will require sponsors to submit varying – rather than uniform – information with new animal drug applications, as deemed appropriate for the particular submission1. The rule comes into force on 8 March 2010.
You may also be interested in...
Following the announcement in the US that ranitidine drugs must be withdrawn from the market, the European Medicines Agency told the Pink Sheet it would decide on the fate of these medicines in the EU after wrapping up its own inquiry.
EU drug industry federation, EFPIA, is concerned that an increase in protectionist trade measures by some countries could result in tit-for-tat policies that could hamper the global response to contain COVID-19.
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Sixty-nine guidance documents have been posted on the tracker since its last update.